We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed at $113.87 in the latest trading session, marking a -1.36% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.09%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq increased by 1.91%.
Shares of the pharmaceutical company have appreciated by 2.16% over the course of the past month, underperforming the Medical sector's gain of 3.16%, and outperforming the S&P 500's gain of 0.29%.
The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on August 4, 2026. The company's earnings per share (EPS) are projected to be $2.1, reflecting a 1.41% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $16.28 billion, reflecting a 3.02% rise from the equivalent quarter last year.
MRK's full-year Zacks Consensus Estimates are calling for earnings of $5.17 per share and revenue of $66.79 billion. These results would represent year-over-year changes of -42.43% and +2.73%, respectively.
Investors should also note any recent changes to analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Merck is currently a Zacks Rank #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 22.34. This represents a premium compared to its industry average Forward P/E of 15.47.
Also, we should mention that MRK has a PEG ratio of 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.6 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 97, this industry ranks in the top 40% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know
Merck (MRK - Free Report) closed at $113.87 in the latest trading session, marking a -1.36% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.09%. On the other hand, the Dow registered a gain of 0.14%, and the technology-centric Nasdaq increased by 1.91%.
Shares of the pharmaceutical company have appreciated by 2.16% over the course of the past month, underperforming the Medical sector's gain of 3.16%, and outperforming the S&P 500's gain of 0.29%.
The investment community will be closely monitoring the performance of Merck in its forthcoming earnings report. The company is scheduled to release its earnings on August 4, 2026. The company's earnings per share (EPS) are projected to be $2.1, reflecting a 1.41% decrease from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $16.28 billion, reflecting a 3.02% rise from the equivalent quarter last year.
MRK's full-year Zacks Consensus Estimates are calling for earnings of $5.17 per share and revenue of $66.79 billion. These results would represent year-over-year changes of -42.43% and +2.73%, respectively.
Investors should also note any recent changes to analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Merck is currently a Zacks Rank #3 (Hold).
In the context of valuation, Merck is at present trading with a Forward P/E ratio of 22.34. This represents a premium compared to its industry average Forward P/E of 15.47.
Also, we should mention that MRK has a PEG ratio of 2.6. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.6 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 97, this industry ranks in the top 40% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.